Form 8-K - Current report:
SEC Accession No. 0001140361-25-017962
Filing Date
2025-05-08
Accepted
2025-05-08 16:16:17
Documents
13
Period of Report
2025-05-02
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

Document Format Files

Seq Description Document Type Size
1 8-K ef20048578_8k.htm   iXBRL 8-K 29744
  Complete submission text file 0001140361-25-017962.txt   168979

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atai-20250502.xsd EX-101.SCH 3973
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20250502_lab.xml EX-101.LAB 22690
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20250502_pre.xml EX-101.PRE 16546
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20048578_8k_htm.xml XML 4211
Mailing Address WALLSTRASSE 16 BERLIN 2M 10179
Business Address WALLSTRASSE 16 BERLIN 2M 10179 49 89 2153 9035
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 25926369
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)